

Reduction of UV-Induced Skin Tumours in Hairless Mice by Topical Non-Steroidal Anti-Inflammatory Drugs

Suong N T Ngo^{1,2*}

¹*School of Animal & Veterinary Sciences, The University of Adelaide, Roseworthy, SA 5371, Australia.*

²*School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5000, Australia.*

ABSTRACT

Aims: Inhibition of ultraviolet-A and -B (UVA+B) skin tumour formation by topical treatment with non-steroidal anti-inflammatory drugs (NSAIDs) was investigated in SKH-1 hairless mice.

Methodology: A UV skin tumour study was designed. Group of mice were irradiated with daily doses of UVA+B for approximately 10 min per day, 5 days per week for 10 weeks. After this 10-week, there was no further UV-exposure. The integrated UV-A irradiance (280-320 nm) was 2.4×10^{-4} W/cm² and the UV-B irradiance (320-400 nm) was 1.8×10^{-3} W/cm². Mice were divided into 4 groups (n=20 per group). Group 1 was treated with methanol; Group 2 received 2% indomethacin in methanol; Group 3 received 2% paracetamol in methanol; Group 4 received 2% flurbiprofen in methanol. All groups received their treatment once a day, five days per week for 25 weeks. Mice were euthanized after 35 weeks.

Results: The test NSAIDs in methanol were effective in reducing the incidence and size of the skin tumours induced by UVA+B, with a significantly lower average number and/or area of skin tumours observed in the NSAID-treated mice compared to the methanol control animals ($P < .05$).

Conclusion: The results support the hypothesis that topically applied indomethacin, paracetamol, and flurbiprofen can provide protection against skin cancer, even when applied well after the skin has been exposed to the damaging effects of UV-light.

Key words: Chemoprevention; UV-induced skin tumour; non-melanoma; NSAIDs; topical formulations; skin cancer.

* Corresponding author: Suong N T Ngo, PhD, The University of Adelaide, Roseworthy Campus, Roseworthy, SA 5371, Australia. Email. suong.ngo@adelaide.edu.au

1. INTRODUCTION

Skin cancer is the most common type of cancer for males and females in the white population [1]. Among the various malignant skin cancer types, non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) is most common, and is a source of significant morbidity. Basal cell carcinoma represents about 80% of all reported skin cancers, while squamous cell carcinoma is about 16%, and melanomas represent about 4% [1,2]. Most NMSC occurs in people over 40 years of age, and incidence rates in Australia are believed to be the highest in the world [3]. A 2-fold increase in NMSC incidence has also been seen in the United States from 1994 to 2006 [4]. People with light complexions, fair or red hair and who tend to burn easily on exposure to the sun (Fitzpatrick skin grades 1 and 2) are more prone to develop NMSC than those with dark-skin, and males appear to be at higher risk [3].

Once treated for a NMSC, the risk of developing a new NMSC is highest in the subsequent year [3]. From an early review of 7 studies, it has been established that the 3-year cumulative risk for a subsequent NMSC is on average 44% [5]. There is also a strong association between the risk of developing a subsequent skin cancer and the number of prior skin tumours - that is, the more prior skin cancers, the higher the risk. In one study, the risk was increased from 38% for patients with fewer than 3 previous NMSC to 93% for patients with 3 to 9 previous NMSC [6]. Healthcare costs associated with the treatment of skin cancers are over 500 million annually in the United States alone, and it has been estimated that at current rates, 1 in 5 Americans will develop a skin cancer of some sort during their lifetime [7,8]. Clearly skin cancer is a major worldwide health problem and is a very costly disease to treat and manage.

There is a causal relationship between excessive exposure to solar ultraviolet (UV) radiation and incidence of skin cancers [3,9]. UV light has been reported as being the main aetiology of NMSC due to DNA damages, such as the creation of cyclobutane dimers and nucleotide mutations [9]. Moreover, p53-gene mutations resulted from UV light could inactivate the p53-gene's ability to inhibit tumor promotions in mutated cells [10]. Preventive methods for NMSC include standard sun protection behaviours, such as applying sunscreen creams with high SPF (sun protection factor), avoiding UV peak hours or periods, and minimising exposure to UV light with protective clothing. As total avoidance of sun exposure would seem unrealistic, other interventions to prevent NMSC are needed. This is greatly beneficial for patients with precursor lesions such as Actinic keratosis, as chemoprevention may inhibit the development of the condition into malignancy [11].

Earlier studies have shown that non-steroid anti-inflammatory drugs (NSAIDs) have a potential role in cancer prevention, including NMSC [12-15] by inhibition of cyclooxygenase enzymes COX-1 and COX-2, which are involved in carcinogenesis [16]. Chemically, NSAIDs are divided into a number of subclasses. They include the salicylic acid derivatives - e.g. aspirin, the indole and indene acetic acids - e.g. indomethacin, the heteroaryl acetic acids - e.g. diclofenac, and the arylpropionic acid derivatives - e.g. flurbiprofen [17]. Paracetamol is considered as an atypical NSAID as it is a weak inhibitor of COXs. Several studies have reported that COX-2 is up-regulated in many forms of cancer, including human colorectal adenocarcinoma, breast, cervical, prostate, lung and skin tumours [18,19], and have indicated a relationship between the NSAID antiproliferative effect and COX inhibition [20-23]. Several lines of evidence also suggested that antiproliferative effects of NSAIDs are mediated via mechanisms that are at least partly independent of COX inhibition [22,24-27]. The role of COX inhibition in NSAID antiproliferative effect is presently unclear. Recently, a study by Sørensen also reported that the use of NSAID, including non-selective NSAIDs, overall reduced the risk of certain types of skin cancer [28].

To test the relative effectiveness of NSAIDs as anticancer agents, a UV skin tumour study in hairless mice was designed. It was found that topical NSAIDs from 3 subclasses; indomethacin, flurbiprofen, and paracetamol can provide protection against skin cancer even when applied well after the skin has been exposed to the damaging effects of UV-light. The results of the tumor study and the effects of the three test NSAIDs, including indomethacin, flurbiprofen, and paracetamol that has a weak COX inhibition action are presented in this paper.

2. MATERIALS AND METHODS

2.1 Chemicals and Reagents

Indomethacin, paracetamol, and flurbiprofen were obtained from the Sigma Chemical Company (Castle Hill, NSW, Australia). Methanol and other chemicals were purchased from Biolab (Clayton, VIC, Australia). All other chemicals were purchased commercially and were of analytical grade.

2.2 Mice

All animals received humane care according to the "Australian code for the care and use of animals for scientific purposes" (National Health and Medical Research Council, NHMRC, AE-16 7th Edition 2004). **The Animal Ethics Committee** at The University of South Australia approved the study protocols for all animal experiments.

Female SKH-1 mice were obtained from the Animal Resource Centre (Perth, Western Australia) at four weeks of age. Animals were randomly allotted to one of four treatment groups and allowed free access to a standard diet formulated according to the American Institute of Nutrition (AIN-89 diet, Glen Forrest Feeds, Perth, WA, Australia). The animals were acclimatized and caged together in groups of 10 mice. The mice were maintained under standard conditions of a 12 h dark/12 h light cycle, at the temperature of 24±2 °C, and relative humidity of 50 ± 10%.

2.3 UV Source

A purpose-built apparatus was used for UV irradiation. The UV emission was produced by 6 UV-A lamps (model 40BL, Sylvania) symmetrically housed around a single UV-B lamp (model FL40SE, Philips). The spectrum was measured with a spectroradiometer (model IL 1700, International Light, Newburyport, MA). The integrated UV-A irradiance (280-320 nm) was $2.4 \times 10^{-4} \text{ W/cm}^2$ and the UV-B irradiance (320-400 nm) was $1.8 \times 10^{-3} \text{ W/cm}^2$.

2.4 Irradiation of Mice

After one week of acclimatization, animals in all groups were exposed to UV-A+B approximating solar UV emission as described above. Irradiation was commenced at 5 min/day and increased to a maximum of 10 min/day. Animals showing undue reddening of the skin (i.e., >2 minimal erythematous dose) were not irradiated further until the erythema had disappeared. Differences between cumulative doses did not exceed 1% of the total UV exposure. No mice exhibited any evidence of blister formation or skin peeling. Mice were irradiated once daily, 5 days per week for 10 weeks. After this 10-week irradiation, there was no further UV exposure.

2.5 Tumor Study

Mice in all groups (n = 20 per group) were irradiated daily for 10 weeks with UVA+B as described above. After exposure to UV for 10 weeks, mice were painted dorsally with (Group 1) 70% methanol, (Group 2) 2% indomethacin in 70% methanol, (Group 3) 2% paracetamol in 70% methanol, (Group 4) 2% flurbiprofen in 70% methanol. The selection of the dose of 2% of topical NSAID was based on preliminary experiments testing a range of concentrations of NSAIDs (from 0.5% up to 3%) on a small number of animals.

All groups received their treatment once a day, five days per week for 25 weeks. Animals were monitored daily for their appearance, and as papillomas or tumours appeared, they were counted and measured regularly. After 35 weeks, the experiment was ended, and all the mice were euthanized with a lethal dose of pentobarbital sodium (Nembutal).

2.6 Statistical Analysis

Statistical analysis was performed using Microsoft Excel software. Tumour multiplicity and total tumor area were compared between the control group and the NSAID treated groups. Tumor multiplicity, expressed as the mean number of tumours, the mean number of tumours plus papillomas per animal, and the total affected area were analysed by Student's *t* test. A *P* value < .05 was considered to be significant. Data concerning the tumor area were transformed using the square root of the area, prior to performing the Student's *t* test. Data are presented as mean ± SD of total animals/group.

3. RESULTS

3.1 Mice Survival

The majority of the mice survived the full 35-week study (see Table 1). The deaths were higher in two of drug treatment groups than the placebo. A number of mice in the indomethacin group did not survive the entire experimental period and died due to noticeable NSAID's toxicity, such as GI disturbance, bleeding which may be possibly resulted from systemic absorption of indomethacin. Two mice in the flurbiprofen group died in week 30 and 31 of the study. No drug toxicity or other causes of death were observed for other groups.

Table 1. Number of Surviving Mice in Each Group During 25 weeks of Topical Treatment with 2% Indomethacin, or 2% Paracetamol, or 2% Flurbiprofen^a

Week number	24	25	26	27	28	29	30	31	32	33	34	35
Placebo	20	20	20	20	20	20	20	20	20	20	19	19
Paracetamol	20	20	20	20	20	20	20	20	20	20	20	20
Flurbiprofen	20	20	20	20	20	20	19	18	18	18	18	18
Indomethacin	20	20	19	19	18	17	15	15	15	15	15	15

^a Each group, originally contained 20 mice, which were subjected to 10 week UV-irradiation, then 25 week topical drug treatment

3.2 Evaluation of Chemopreventive Effects

The incidence of tumours, the mean number of tumours and mean number of tumours plus papillomas, and the total areas found in the various groups at the end of the 35-week study are summarized in Table 2. No tumours or papillomas were present in mice

during the 10 weeks of UV exposure. Data are presented as tumours, and tumours plus papillomas as the natural progression of UVA+B-induced skin cancer is from the initiated cell to a benign papilloma to cancer (defined as an invasive lesion) and in some cases the distinction could not be made unequivocally.

The incidence of UVA+B-induced skin tumours was reduced in the groups treated with indomethacin and paracetamol, to about two-thirds and four-fifths that of the methanol only group, respectively. The mean number of tumours was reduced in the NSAID treated groups and was statistically significant for paracetamol ($P < .05$), but not for indomethacin and flurbiprofen possibly due to the large standard errors. The mean number of tumours plus papillomas was also lower and was statistically significant for indomethacin and paracetamol ($P < .05$), not for flurbiprofen.

Table 2. Tumor multiplicity and burden in mice receiving topical treatment with 2% indomethacin, paracetamol, or flurbiprofen after 10-week UV-A + B exposure

	Survival ^a	Percentage of mice with tumours	Tumours ^b Number	Area (mm ²)	Tumours & Papillomas ^b
Methanol	19	68%	1.53 ± 0.96	14.68 ± 11.24	1.76 ± 0.83
Indomethacin	15	53%	0.66 ± 0.51	1.1 ± 0.48*	1.16 ± 0.40*
Paracetamol	20	45%	1.00 ± 0.57*	3.41 ± 4.00	1.28 ± 0.48*
Flurbiprofen	18	61%	0.88 ± 0.60	5.27 ± 4.19*	1.55 ± 0.78

^aEach group originally contained 20 mice: survival values are the number of mice alive after 35 weeks.

^b Mean ± S.D.

*Mean number of tumours, mean area of tumours, and mean number of tumours + papillomas significantly lower than methanol control group at $P < .05$ by Student's *t* test.


The mean area of the tumours and the mean area of tumours plus papillomas were also calculated as an index of tumour burden on the mice. Both the mean area of tumours (see Table 2) and the mean area of tumours plus papillomas were significantly reduced in mice treated with indomethacin and flurbiprofen than that in methanol control animals ($P < .05$); but were not statistically significant for paracetamol. The mean area of tumours plus papillomas is presented in Fig. 1.

DISCUSSION

In this study, inhibition of UVA+B-induced skin tumour formation by 3 test NSAIDs from different subclasses; indomethacin, flurbiprofen, and paracetamol adds further support to the hypothesis that NSAIDs can provide protection against skin cancer, even when applied well after the skin has been exposed to the damaging effects of UV-light. This finding is particularly significant given the latency period of skin cancer in humans.

The chemopreventive treatments with systemic NSAIDs, including aspirin, ibuprofen, indomethacin and paracetamol have previously been shown to reduce the risk of developing NMSC [12-14,29]. Previous human population-based case-control studies demonstrated a reduced risk of having NMSC in ibuprofen [12,13], indomethacin [12], paracetamol [13] and aspirin users [13]. Lower risk of NMSC with paracetamol use has

223
224
225
226
227



231
232
233
234
235
236
237
238
239

Fig. 1. The mean total area of tumours and papillomas per mouse in the NSAID treated groups compared to the placebo at the end of the study.

Data are presented as mean $\pm$ SD of total animals/group

also been found in previous human prospective study, with a reduced risk associated with a higher frequency of use ($P = .04$) [29]. An RCT in 1402 AK (actinic keratosis) patients resulted in a reduction in the risk of developing NMSC for aspirin treatment [14]. It has earlier been shown that orally administered NSAID indomethacin [30] and celecoxib could inhibit development of UVB induced skin tumours in mice [30-33] and in human RCT [34]. Unfortunately, because of the toxicity of indomethacin due to systematic absorption, it was not possible to study its effects at higher concentrations. Regarding the use of topical NSAIDs, only one earlier study has shown a delayed onset and reduced development of skin tumours in mice using celecoxib combined with zileuton, a 5-lipoxygenase inhibitor [35]. In the present study, topical indomethacin was shown to have the greatest protective effects compared to paracetamol and flurbiprofen. However, it was also associated with a lower survival of mice, which was consistent with that reported in the literature. Overall, 3 test compounds, including week COX inhibitor paracetamol, were effective in reducing the mean number and/or area of skin tumours in hairless mice that had been exposed to UV A+B light only during earlier stages of their life (before drug treatment was commenced). The results of this study further support the potential use of NSAIDs as skin cancer chemo-preventive agents.

257
258
259

CONCLUSION

260 The results support the hypothesis that topically applied indomethacin, paracetamol, and
261 flurbiprofen can provide protection against skin cancer, even when applied well after the
262 skin has been exposed to the damaging effects of UV-light. As topical administration of
263 drugs would lead to less side effects compared with systemic administration, the idea of
264 topical NSAID to prevent UV-induced NMSC with minimal cardiovascular complications
265 and gastrointestinal bleeding is worth being further investigated.

266

267

268 **AUTHOR' CONTRIBUTIONS**

269

270 The sole author designed, analyzed and interpreted and prepared the manuscript.

271

272 **CONSENT**

273

274 It is not applicable.

275

276

277 **COMPETING INTERESTS**

278

279 Author has declared that no competing interests exist.

280

281

REFERENCES

1. Guy GP, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and nonmelanoma skin cancer: a systematic review of the literature. *Pharmato Economics*. 2011;29(10):863-874.
2. Trakatelli M, Ulrich C, delMarmol V, Euvrard S, Stockfleth E, Abeni D. Epidemiology of non-melanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. *Br J Dermatol*. 2007;156(Suppl):1-7.
3. Diepgen TL, Mahler V. The epidemiology of skin cancer. *Br J Dermatol*. 2002;146(61)(Suppl):1-6.
4. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, Coldiron BM. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. *Arch Dermatol*. 2010;146(3):283-287.
5. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer. *Arch Dermatol*. 2000;136:1524-1530.
6. Czarnecki D, Mar A, Staples M, Giles G, Meehan CL. The development of non-melanocytic skin cancer in people with a history of skin cancer. *Dermatology*. 1994;184:364-367.
7. Stern RS. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. *Arch Dermatol*. 2010;146(3):279-282.
8. Rigel DS. Photoprotection: a 21st century perspective. *Br J Dermatol*. 2002;146(61)(Suppl):34-37.
9. Brash DE. Sunlight and the onset of skin cancer. *Trends Genet*. 1997;13(10):410-414.
10. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Pontén J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. *Proc Natl Acad Sci USA*. 1991;88(22):10124-10128.
11. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. *J Am Acad Dermatol*. 2000;42(Suppl):4-7.
12. Johannesdottir SA, Chang ET, Mehnert F, Schmidt M, Olesen AB, Sørensen HT. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. *Cancer*. 2012;118(19):4768-4776.
13. Torti DC, Christensen BC, Storm CA, Joan F, Ann EP, Michael SZ, et al. Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study. *J Am Acad Dermatol*. 2011;65(2):304-312.
14. Clouser MC, Roe DJ, Foote JA, Harris RB. Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the KICAP-AK trial. *Pharmacoepidemiol Drug Saf*. 2009;18(4):276-283.
15. Asgari M, Emily W, Chren M. Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma. *Dermatol. Surg*. 2004;30:1335-1342.
16. Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. *Prog. Exp. Tumor Res*. 2003;37:1-24.
17. Hardman JG, Limbird LE Eds. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. McGraw Hill Publishers, New York, USA; 1996.
18. Chun KS, Surh YJ. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. *Biochem. Pharmacol*. 2004;68:1089-1100.
19. Fischer SM, Pavone A, Mikulec C, Langenbach R, Rundhaug JE. Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis. *Mol. Carcinog*. 2007;46:363-371.
20. Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). *J. Natl. Cancer Inst*. 1998;90:1609-1620.
21. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in APC716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). *Cell*. 1996;87:803-809.

338 22. Elder D, Halton D, Hague A, Paraskeva C. Induction of apoptotic cell death by a
339 cyclooxygenase-2 (COX-2)-selective nonsteroidal antiinflammatory drug: Independence
340 from COX-2 protein expression. *Clin. Cancer Res.* 1997;3:1679-1683.

341 23. Rigas B, Shiff SJ. Is inhibition of cyclooxygenase required for the chemopreventive
342 effect of NSAIDs in colon cancer? A model reconciling the current contradiction. *Med.*
343 *Hypothesis.* 2000;54:210-215.

344 24. Thompson H, Jiang C, Lu J, Mehta RG, Piazza GA, et al. Sulfone metabolite of
345 sulindac inhibits mammary carcinogenesis. *Cancer Res.* 1997;57:267-271.

346 25. Wechter W, Kantoci D, Murray ED Jr, Quiggle DD, Leipold DD, Gibson KM, et al. R-
347 Flurbiprofen chemoprevention and treatment of intestinal adenomas in the APCMin/+
348 mouse model: Implications for prophylaxis and treatment of colon cancer. *Cancer Res.*
349 1997;57:4316-4324.

350 26. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, et al. Effects of
351 nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in
352 colon cancer cells by a prostaglandin-independent pathway. *Biochem. Pharmacol.*
353 1996;52:237-245.

354 27. Liu G, Ma W, Bode AM, Zhang Y, Dong Z. NS-398 and proxicam suppress UVB-
355 induced activator protein 1 activity by mechanisms independent of cyclooxygenase 2. *J.*
356 *Biol. Chem.* 2003;278:2124-2130.

357 28. Sørensen HT. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer.
358 *Cancer.* 2012;118:4768-4776.

359 29. Jeter JM, Han J, Martinez ME, Alberts DS, Qureshi AA, Feskanich D. Non-steroidal
360 anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health
361 Study. *Cancer Causes Control* 2012;23(9):1451-1461.

362 30. Fischer S, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, et al.
363 Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and
364 indomethacin against ultraviolet-induced skin carcinogenesis. *Mol Carcinog*
365 1999;25:231-240.

366 31. Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyshyn TM. Inhibition of
367 cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical
368 celecoxib treatment. *Mol Carcinog* 2003;38:49-58.

369 32. Orengo IF, Gerguis J, Phillips R, Guevara A, Lewis AT, Black HS. Celecoxib, a
370 cyclooxygenase 2 inhibitor as potential chemopreventive to UV-induced skin cancer: a
371 study in the hairless mouse model. *Arch Dermatol.* 2002;138:751-755.

372 33. Fischer SM, Conti CJ, Viner J, Aldaz CM, Lubet RA. Celecoxib and
373 difluoromethylornithine in combination have strong therapeutic activity against UV-
374 induced skin tumors in mice. *Carcinogenesis.* 2003;24:945-952.

375 34. Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, et al.
376 Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-
377 blind, placebo-controlled trial. *J Natl Cancer Inst.* 2010;102(24):1835-1844.

378 35. Fegn L, Wang Z. Topical chemoprevention of skin cancer in mice, using combined
379 inhibitors of 5-lipoxygenase and cyclooxygenase-2. *J Laryngol Otol.* 2009;123(8):880-
380 884.